ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform

By: Newsfile

Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.

Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's next-generation, cloud-native architecture, expected to deliver immediate value through:

  • Infrastructure-as-Code (IaC): built to be automated and a more secure and error-free infrastructure that replaces legacy manual processes.
  • Unified Storage & Workflows: Centralized, scalable code management for all projects and services, reducing silos and technical debt.
  • Future-Ready Foundation: One-click deployment, automated security, and seamless integration with AWS, GCP, and Azure.

With this installation complete, the iSpecimen Marketplace® now operates on a modernized digital backbone that is designed to ensure reliability, scalability, and faster time-to-market.

"The successful completion of Milestone 1 is a major step forward in iSpecimen's mission to create the most efficient and secure marketplace in our industry," said Robert Lim, CEO of iSpecimen. "By leveraging Salestack's advanced platform, we are working to future-proof our systems, eliminating long-standing inefficiencies, and preparing for the next phases of integration, customization, and automation."

The completion of Milestone 1 is expected to provide several immediate and long-term benefits significant to the Company:

  1. Improved Reliability: Resilient, multi-cloud architecture reduces risk of outages and downtime.
  2. Enhanced Security: Automated safeguards designed to eliminate vulnerabilities from manual provisioning.
  3. Accelerated Innovation: Development cycles are faster, enabling quicker delivery of features to customers and stakeholders.

This accomplishment positions iSpecimen to advance to Milestone 2 (Integration), which will focus on connecting all parts of the Company's business to the Salestack platform to create end-to-end efficiency across operations, customer engagement, and data management.

"With Milestone 1 complete, we have implemented a robust and scalable platform that sets the stage for innovation," continued Mr. Lim. "As we progress through the next milestones, we expect to unlock even greater efficiencies, enhance our marketplace capabilities, with the goal of creating significant long-term value for our shareholders, partners, and customers," he concluded.

About iSpecimen

iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Safe Harbor Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; the inability or difficulty to obtain planned benefits from the Company's digital transformation program powered by Salestack Solutions; and risks and uncertainties associated with market conditions and the Company's ability to meet future milestones with Salestack. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contacts:

info@ispecimen.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263101

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.